Charles River Laboratories International Inc (CRL) Stock AnalysisCRLCharles River Laboratories International Inc

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes businesses that provide foundational tools that enable its clients to discover new molecules: Research Models and Research Model Services. Its Discovery and Safety Assessment (DSA) segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including the in vitro, in vivo, and in silico studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Charles River Laboratories is a good buy right now due to its recent strong earnings report of $3.02 per share, surpassing expectations, and a raised 2026 earnings forecast to $11.15-$11.45 per share. The current price of $300.15 is well below the average analyst price target of $340, suggesting significant upside potential. However, the company has faced recent net income losses, with a net margin of -0.08% in Q2 2026, indicating some risk in profitability. Overall, the strong revenue growth and positive analyst sentiment outweigh the risks, making it a favorable investment opportunity.

16 analysts cover CRL: 8 rate it Buy, 8 Hold and 0 Sell. The average price target is 226.70.